(Reuters) – Shareholders in Johnson & Johnson approved on a binding advisory basis CEO Alex Gorsky's salary plan of $ 29.6 million for 2020 at the health care company's annual general meeting on Thursday.
The approval was a win for J&J, which faced a "vote no" campaign for its executive salary from the Illinois State Treasurer's Office, a member of the Investors for Opioid and Pharmaceutical Accountability (IOPA), a 61-member coalition with $ 4.2 trillion in assets under management. [19659002IllinoisTreasurerOfficeuppmanadeaktieägarnaattavvisaGorskyslöneftersomdetutesluterfrånsinberäkningavaktietilldelningarcirka9miljarderdollarikostnaderrelateradetilltusentalsrättegångarsomhävdarattdethjälptetillattdrivauppdenamerikanskaopioidkrisenochattspåravasbestidesstalkpulverorsakadecancer[1
The final results of the vote, including the total number of J & J investors who approved the salary arrangement, will be released in the coming days.
Companies will usually engage with shareholders and possibly adopt changes in their remuneration practices if they receive a significant number of votes against their remuneration. companies even if you get as much as 30% support "on a" vote no "campaign, says Donna Meyer, Head of Shareholder Advocacy at Mercy Investment Services Inc. You get the company to talk to you about it. ”
Herr. Gorsky also answered a question from an investor about the possible link between J & J's COVID-19 vaccine and a very rare but serious thrombotic condition that led to a pause in the US in its use.
He said the company was looking forward to a US. regulatory meeting and review of the issue scheduled for Friday.
"We strongly support awareness of the signs and symptoms of this extremely rare event to ensure proper diagnosis, appropriate treatment and prompt reporting by healthcare professionals," Gorsky said. . "We continue to believe in the positive benefit-risk profile of our vaccine."